SALVOVAR | A EUROPEAN MULTI-DISCIPLINARY CLINICAL PROJECT MEANT TO IMPROVE THE MANAGEMENT OF PATIENTS WITH POOR PROGNOSTIC OVARIAN CANCER AFTER NEOADJUVANT CHEMOTHERAPY: RESTORING HOPE, SALVAGING LIVES

Summary
The standard medical-and-surgical treatment of ovarian carcinoma patients relies on a systemic chemotherapy (carboplatin-paclitaxel), a tumor debulking surgery meant to be complete (no post-operative residual lesion), and a subsequent maintenance treatment with modern targeted agents. Recent studies identified a patient population (~14,000 patients / year in Europe), whose prognostic is poor (5 year-overall survival (OS)
Resources Show all and search (0)
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/101104469
Start date: 01-05-2023
End date: 30-04-2028
Total budget - Public funding: 6 823 071,25 Euro - 6 823 071,00 Euro
Cordis data

Original description

The standard medical-and-surgical treatment of ovarian carcinoma patients relies on a systemic chemotherapy (carboplatin-paclitaxel), a tumor debulking surgery meant to be complete (no post-operative residual lesion), and a subsequent maintenance treatment with modern targeted agents. Recent studies identified a patient population (~14,000 patients / year in Europe), whose prognostic is poor (5 year-overall survival (OS)

Status

SIGNED

Call topic

HORIZON-MISS-2022-CANCER-01-03

Update Date

31-07-2023
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon Europe
HORIZON.2 Global Challenges and European Industrial Competitiveness
HORIZON.2.1 Health
HORIZON.2.1.0 Cross-cutting call topics
HORIZON-MISS-2022-CANCER-01
HORIZON-MISS-2022-CANCER-01-03 Pragmatic clinical trials to optimise treatments for patients with refractory cancers
Search
Search on Google
Search on Bing
Search on DuckDuckGo
Organisations
Show all (11)
Powered by Chris Decubber BV